Technical Analysis for PCRX - Pacira Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bearish Signal Line Cross | Bearish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Pocket Pivot | Bullish Swing Setup | -0.41% | |
Bollinger Band Squeeze | Range Contraction | -0.41% | |
Fell Below 20 DMA | Bearish | 0.10% | |
Bollinger Band Squeeze | Range Contraction | 0.10% | |
Multiple of Ten Bearish | Other | 0.10% | |
Down 3 Days in a Row | Weakness | 0.10% | |
Down 4 Days in a Row | Weakness | 0.10% | |
20 DMA Support | Bullish | -3.30% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 18 hours ago |
Fell Below Previous Day's Low | about 20 hours ago |
Down 2 % | about 20 hours ago |
Down 1% | about 20 hours ago |
Down 1% | 4 days ago |
Get a Trading Sidekick!
- Earnings date: 05/01/2024
Pacira Pharmaceuticals, Inc. Description
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers worldwide. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company markets EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia; and DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. Its product pipeline comprise EXPAREL that has completed Phase II clinical trials for postsurgical analgesia-nerve block administration; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate that is in preclinical trials for the treatment of rheumatoid arthritis and oncology, as well as Bupivacaine Liposome Injectable Suspension for veterinary postsurgical analgesia. Pacira Pharmaceuticals, Inc. has a development and commercialization agreement, and related supply agreement with Aratana Therapeutics, Inc. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Cancer Pharmaceutical Immune System Pain Surgery Pharmaceutical Products Lymphoma Pharmacology Rheumatoid Arthritis Drug Delivery Suspension Acute Pain Nerve Bupivacaine Drug Delivery Technology Meningitis Piperidines Liposome Local Anesthetic Surgical Site Methotrexate
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 48.6 |
52 Week Low | 25.93 |
Average Volume | 516,323 |
200-Day Moving Average | 32.86 |
50-Day Moving Average | 30.88 |
20-Day Moving Average | 29.91 |
10-Day Moving Average | 30.14 |
Average True Range | 1.05 |
RSI (14) | 43.50 |
ADX | 21.25 |
+DI | 13.35 |
-DI | 25.41 |
Chandelier Exit (Long, 3 ATRs) | 28.31 |
Chandelier Exit (Short, 3 ATRs) | 31.05 |
Upper Bollinger Bands | 31.15 |
Lower Bollinger Band | 28.68 |
Percent B (%b) | 0.25 |
BandWidth | 8.27 |
MACD Line | -0.18 |
MACD Signal Line | -0.17 |
MACD Histogram | -0.0136 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 30.67 | ||||
Resistance 3 (R3) | 30.62 | 30.12 | 30.44 | ||
Resistance 2 (R2) | 30.12 | 29.77 | 30.14 | 30.36 | |
Resistance 1 (R1) | 29.71 | 29.55 | 29.46 | 29.75 | 30.28 |
Pivot Point | 29.20 | 29.20 | 29.08 | 29.23 | 29.20 |
Support 1 (S1) | 28.79 | 28.85 | 28.54 | 28.83 | 28.30 |
Support 2 (S2) | 28.29 | 28.64 | 28.31 | 28.22 | |
Support 3 (S3) | 27.87 | 28.29 | 28.14 | ||
Support 4 (S4) | 27.91 |